anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease (CKD), a progressive decline in kidney function, is a growing health problem: 13% of adults in the US have CKD. Among patients with CKD, the risk of progression to irreversible loss of kidney function (end-stage renal disease, ESRD) is about 1% per year. In addition, adjusted mortality is approximately four times greater among those with CKD compared to those without. For ESRD, apart from dialysis and kidney transplant, no treatment exists. CKD increases urea levels in bodily fluids leading to a dominance of urease-containing bacteria in the gut. Such dysbiosis results in decreased production of the short chain fatty acid, butyrate and decreased health of the colonic epithelial barrier. Consequently, bacterial toxins translocate into the bloodstream, promoting inflammation. Moreover, production of uremic toxins such as indoxyl and p-cresyl sulfates are also increased, resulting in further kidney injury.

CKD patients are prescribed a diet low in protein, fiber and symbiotic organisms, which reduces complications like hyperkalemia, but also contributes to the dysbiosis. Re-formulating the CKD diet may improve the clinical management of CKD. The investigators's overall hypothesis is that changes in the microbial diversity, xeno-proteins and xeno-metabolites correlate with CKD progression, and microbiome-directed therapies can be used to slow the disease. In this study, the investigators will determine the tolerability of supplemental resistant starch (RS). Secondary aims are to determine if a diet high in resistant starch changes fecal butyrate concentrations, the make-up of the gut microbiome and the concentrations in the blood of uremic toxins produced by the gut microbiome. This study will help in the design of a future study with the aim of understanding if a high resistant starch diet can slow the progression of chronic kidney disease.
The invention provides a health care product reducing blood fat auxiliarily. The raw materials comprise broadleaf holly leaves, red sage roots, hawthorns, lotus leaves and pseudo-ginseng. The raw materials also comprise mulberry leaves, radix ophiopogonis, chaenomeles speciosa and cattail pollen ketone. The raw materials of the health care product also can comprise radix paeoniae rubra, safflowers, rhizoma sparganii, curcuma zedoary, radix curcumae, angelica sinensis, sappanwood and agilawood. The health care product is a pure traditional Chinese medicine preparation, contains no sugar, and is convenient to take for the elderly and diabetes patients. The active ingredient contents are high and volatile active ingredients are reserved furthest. The bioavailability is high, the impurity content is low, and there is no raw medicine powder. The health care product is prepared through a pressing method or a dropping preparation method, is formed at one time and has a whole sealing dosage form, and an unqualified phenomenon of disintegration after long time storage is avoided. Foreign odor and peculiar smell of some contents can be covered, the traditional Chinese medicine volatile components, traditional Chinese medicine components with adverse smell and traditional Chinese medicine preparations have special smell, after preparation into soft capsules, volatilization is not easy, adverse smell can be covered, and the drug quality is raised.
This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
This group will receive an online two-week intervention to train the specificity and savoring of autobiographical memories. During the two-week intervention and the following two weeks, participants will complete continuous assessments (i.e. once a day) rate the their mood (positive and negative affect) as well as the level of positivity, specificity and savoring of positive memories recalled during practice session. For this study, we included continuous assessments to monitor essential project variables throughout the intervention (2 weeks; from Day 0 to Day 15) and then as a follow-up (2 weeks after; from Day 16 to Day 30).
Recent work demonstrates that those who regularly play action video games (AVGs) consistently outperform non-gamer (NG) controls on tests of various cognitive abilities. AVGs place high demands on several cognitive functions and are often engaged with for long periods of time (e.g., over 2 h), predisposing players to experiencing cognitive fatigue. The detrimental effects of cognitive fatigue have been widely studied in various contexts where accurate performance is crucial, including aviation, military, and sport. Even though AVG players may be prone to experiencing cognitive fatigue, this topic has received little research attention to date. In this study, we compared the effect of a cognitively fatiguing task on the subsequent cognitive performance of action video game players and NG control participants. Our results indicated AVGs showed superior spatial working memory and complex attention abilities while showing no difference from NGs on simple attention performance. Additionally, we found that our cognitive fatigue and control interventions did not differentially affect the cognitive performance of AVGs and NGs in this study. This pre-registered study provides evidence that AVGs show superior cognitive abilities in comparison to a non-gaming population, but do not appear more resilient to cognitive fatigue.
Many clinical studies have used 810nm twice a week for 4 weeks. This is the standard.
Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or \<50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
The present invention concerns antibody-like binding protein in the CODV format specifically binding to CD3 and CD123. The bispecific antibodies have biological and immunological specificity to the CD3 antigen and at least one further antigen, which is CD123. Said binding proteins induce low T-cell activation in absence of target cells (expressing CD123), but high activation of T-cells in the presence of target cells. The antibody-like binding protein 7G3 x 20G6 has superior safety compared to 7G3 x OKT3. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
Biologic agents are a group of genetically engineered drugs that target the immune system and have gained a lot of popularity in recent years. They act by interfering with cytokine function or production, inhibiting the "second signal" required for T-cell activation or by depleting B-cells. They are used for the treatment of a wide variety of diseases including Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus (SLE), some types of vasculitis and many more. Many of these pathologies occur in young women during child-bearing years and so it is important for these drugs to not only be safe to use for the patient but also during pregnancy for fetus and child. Many studies are conducted on their safety for the patients but few studies are present on the safety of use during pregnancy. There are even fewer studies that follow up for long term effects on the children outside of the perinatal period.

The goal of the study is to evaluate the effects on the offspring and therefore the safety of using biologic agents during pregnancy and their eventual consequences on children. The effects considered are divided into peri-partum and more long-term effects. Demonstration of safety in children born from mothers who received biologics during pregnancy will pave the way of their use in other women affected by autoimmune diseases unresponsive to standard treatment.
Use the lowest dose effective for the patient. For all BELSOMRA doses, take no more than once per night within 30 minutes of going to bed (with at least 7 hours remaining prior to planned awakening). Time to effect of BELSOMRA may be delayed if taken with or soon after a meal [see Clinical Pharmacology (12.3)].

The recommended dose for BELSOMRA is 10 mg, taken no more than once per night. If the 10 mg dose is well-tolerated but not effective, the dose can be increased. The maximum recommended dose of BELSOMRA is 20 mg taken no more than once per night.
FIELD: medicine. SUBSTANCE: one should introduce liquid medicinal water-containing preparation pretreated with constant electric current at 15 kV/cm intensity, not higher, into the human body in accordance with the pathology detected. Treatment is performed for 30 min, not less. Preparation could be treated by both homogeneous and heterogeneous with constant electric current. EFFECT: higher efficiency of curative impact. 2 cl, 2 ex
In control 'implementation as usual' sites, no facilitation or implementation strategies will be provided. Controls will receive 1) an informational session on the text intervention during grand rounds/staff meetings and 2) flyers to provide patients with intervention enrollment information.
FIELD: medicine, gastroenterology. SUBSTANCE: composition has, mas. p.: bismuth basic nitrate or salicylate, 50-500; tetracyclin hydrochloride, 100-500; and metronidazole, 100-500. Method of treatment involves abolishment of pathogen - pyloric helicobacterium by intake of the indicated composition, 5 times per a day at equal intervals for 12 days. Composition can contain additionally omeprazole or lansoprazole (blockader of proton pump) at amount 20-40 mas. p. that is given once per a day of 5 days in the morning. EFFECT: enhanced effectiveness of treatment, decreased doses and unfavorable by-side effects and treatment time. 5 cl
BACKGROUND: Coronary computed tomography angiography provides valuable information for evaluating the difficulty of chronic total occlusion (CTO) percutaneous coronary intervention. This study aimed to investigate the value of CTO plaque characteristics derived from radiomics analysis for predicting the difficulty of percutaneous coronary intervention.
METHODS: Patients with CTO were retrospectively enrolled from a hospital as training and internal test sets and from the other 2 territory hospitals as external test sets. Radiomics characteristics were extracted from the CTO segment on coronary computed tomography angiography. Radiomics and combined models were developed to predict successful guidewire crossing within 30 minutes (guidewire success) of CTO percutaneous coronary intervention. Subgroup analysis was conducted to investigate the influence of potential risk factors on the radiomics model performance.
RESULTS: A total of 551 patients (median, 60; interquartile range, 52.00-66.00 years, 460 men) with 565 CTO lesions were finally enrolled. In the training, internal test, and external test sets, 203 of 357, 85 of 149, and 38 of 59 CTO lesions achieved guidewire success, respectively. Six radiomics features were selected for constructing the radiomics model. In the external test set, the area under the receiver operating characteristic curve of the radiomics model was significantly higher than prior prediction models (P<0.05 for all) with the area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity of 0.86, 74.58%, 81.58%, and 61.90%, respectively. The performance of the radiomics model was dependent on calcification, CTO location, adjacent branch(es), and operator caseload.
CONCLUSIONS: CTO characteristics revealed by radiomics analysis can be used as effective imaging biomarkers for predicting guidewire success. However, the performance of the radiomics model depends on anatomic and operator factors.
A medicinal antipressor is prepared by the interaction of hippuric acid and urobilinogen or an extract containing urobilinogen. According to an example, urine of horses or other liver-bearing animals is agitated with butyl ether for several hours.  After standing two layers separate, the upper butyl ether layer containing fat &c. being discarded while the lower aqueous layers is slowly evaporated at a temperature not above 170 DEG  F. to reduce its volume.  The aqueous layer is then slightly acidified p  with acetic acid and the evaporation is continued to produce a semi-fluid black mass.  The black mass is extracted with ethyl acetate, the extract being filtered and evaporated to dryness. The residue is dissolved in a mixture of alcohol and chloroform and the solution after filtering is mixed with distilled water. The resulting lower chloroform layer is evaporated to dryness to produce a urobilinogen concentrate.  The concentrate is mixed with hot water and hippuric acid, the mixture being heated until all the urobilinogen concentrate dissolves.  The hot solution is filtered and on cooling, crystals of the antipressor composition separate.  The Specification as open to inspection under Sect. 91 comprises also the preparation of an antipressor composition by reacting benzoic acid with urobilinogen or an extract containing urobilinogen.  This subject-matter does not appear in the Specification as accepted.ALSO:A medicinal anti-pressor composition is prepared by the interaction of hippuric acid and urobilinogen or an extract containing urobilinogen.  According to an example urine of horses or other liverbearing animals is agitated with butyl ether for several hours.  After standing two layers separate, the upper butyl ether layer containing fat &c. being discarded while the lower aqueous layer is slowly evaporated at a temperature not above 170 DEG F. to reduce its volume.  The aqueous layer is then slightly acidified with acetic acid and the evaporation is continued to produce a semi-fluid black mass.  The black mass is extracted with ethyl acetate, the extract being filtered and evaporated to dryness, the residue is dissolved in a mixture of alcohol and chloroform and the solution after filtering is mixed with distilled water.  The resulting lower chloroform layer is evaporated to dryness to produce a urobilinogen concentrate.  The concentrate is mixed with hot water and hippuric acid, the mixture being heated until all the urobilinogen concentrate dissolves.  The hot solution is filtered and on cooling crystals of the anti-pressor composition separate.  For injection the composition may be dissolved in a solution of sodium bicarbonate, the solution being slightly warmed to eliminate generated carbon dioxide; it may also be administered orally in the dry form.  The Specification as open to inspection under Sect. 91 comprises also the preparation of an anti-pressor composition by reacting benzoic acid with urobilinogen or an extract containing urobilinogen.  This subject-matter does not appear in the Specification as accepted.
Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
It is widely postulated that the majority of pathologically elevated extracellular or cell-free DNA (cfDNA) in cancer originates from tumor cells; however, evidence has emerged regarding the significant contributions of other cells from the tumor microenvironment. Here, the effect of cfDNA originating from murine B16 melanoma cells and L929 fibroblasts on B16 cells was investigated. It was found that cfDNAL929 increased the viability and migration properties of B16 cells in vitro and their invasiveness in vivo. In contrast, cfDNAB16 exhibited a negative effect on B16 cells, reducing their viability and migration in vitro, which in vivo led to decreased tumor size and metastasis number. It was shown that cell treatment with both cfDNAs resulted in an increase in the expression of genes encoding DNases and the oncogenes Braf, Kras, and Myc. cfDNAL929-treated cells were shown to experience oxidative stress. Gene expression changes in the case of cfDNAB16 treatment are well correlated with the observed decrease in proliferation and migration of B16 cells. The obtained data may indicate the possible involvement of fibroblast DNA in the tumor microenvironment in tumor progression and, potentially, in the formation of new tumor foci due to the transformation of normal cells.
A method for treatment of an animal for systemic hypotension induced by internal nitric oxide production caused by endotoxin or cytokines. The method involves administering an  alpha 1 adrenergic agonist and an amount of an inhibitor of nitric oxide formation from arginine to restore vascular contractile sensitivity to  alpha 1 adrenergic agonists. A preferred inhibitor of nitric oxide formation is an NG-substituted arginine having at least one hydrogen on a guanidino amino group replaced by another atomic or molecular species, including NG-aminoarginine, NG-nitroarginine, and NG-alkylarginines such as NG-methylarginine, NG-ethylarginine, NG-propylarginine and NG-butylarginine. Arginine derivative inhibitors are preferably of the L configuration and include pharmaceutically acceptable addition salts. Treatment of systemic hypotension in a patient which has been induced by chemotherapy with biologic response modifiers such as tumor necrosis factor or interleukin-2 may be likewise accomplished. Treatment of an animal for systemic hypotension induced by endotoxin, or other bacterial toxins, e.g., septic shock, may also be accomplished by treatment with  alpha 1 adrenergic agonists and an inhibitor such as an arginine derivative, restoring vascular contractile sensitivity to the  alpha 1 adrenergic agonists.
The purpose of this study is to explore the effects of oral lactate ingestion on appetite regulation in humans. To do this males and females will report to the laboratory for 2 experimental sessions completed in a counterbalanced, double-blinded manner. During one session a lactate solution will be ingested, in another session an equimolar sodium chloride solution will be ingested that matches the osmolarity of the lactate condition. Venous blood samples and subjective appetite perceptions will be obtained at five time points during each experimental session. Energy expenditure will be measured through accelerometers placed on the participants anterior thigh by an investigator on the morning the day before the session and worn over the experimental period (day before, day of, day after) recording their physical activity. Energy intake will be tracked using a smartphone mobile application called Keenoa over the same time period the accelerometers are worn.
Placebo is administered intravenously in a multiple ascending dose pattern in four dose levels. Each level includes 2 patients.
PROBLEM TO BE SOLVED: To obtain the subject composition which can give uniform and harmonized make-up and can be used not only for skins and the like but also for eyelashes, eyebrows, nails, hair and the like, by including fibers solubilized in a fat phase with a liquid polyol. SOLUTION: This composition contains fibers which are solubilized in a fat phase with a liquid polyol and are sufficiently longer than their diameter. The polyol has an IOB(inorganic/organic balance) value of preferably 1 to 7, more preferably 1.5 to 5.5. The polyol includes propylene glycol, butylene glycol, glycerol and pantenol. The fibers preferably have a length of 0.1 to 5 mm, an average diameter of 5 to 50 μm, and a count of 0.15 to 30 denier. The fibers include silk, cotton, wool, flax, especially cellulose fibers separated from wood, vegetables or sea algae, polyamide fibers, viscose fibers, and poly p-phenylene terephthalamide fibers.
Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
<P>PROBLEM TO BE SOLVED: To find out an active component having excellent action to suppress the accumulation of neutral fat and to use the component as an agent for suppressing the accumulation of neutral fat and an external preparation for skin for slimming.  <P>SOLUTION: An extract of a plant of the family Dicranaceae having excellent action to suppress the accumulation of neutral fat is used as the neutral fat accumulation suppressing agent. The external preparation for skin for slimming is produced by compounding an external preparation for skin with the extract of a plant of the family Dicranaceae. The food for slimming is produced by compounding a food with the extract of a plant of the family Dicranaceae. The extract of the plant of the family Dicranaceae is preferably an extract of a plant of the genus Dicranum or Campylopus.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants will not undergo any treatment. Continue with usual daily activities and diet for 6 months.
Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
BACKGROUND: Validated syncope risk scores were aimed to predict a cardiac etiology and are mainly used in the decision of hospital admission. Whether these scores could also predict the outcomes of inpatient cardiac evaluation is unknown and was the subject of our study.
METHODS: This was an observational study including consecutive patients admitted for syncope evaluation. All patients completed prolonged electrocardiogram monitoring and an echocardiography before discharge. The area under the receiver-operating characteristic curve (AUC) was used to evaluate the ability of validated risk scores to predict positive inpatient findings. Subsequently, a multivariate regression was performed to identify independent predictors for positive cardiac evaluation, which were then incorporated into the best predictive risk scores.
RESULTS: Three hundred ninety-seven patients were included, 56 (14%) with a positive inpatient cardiac evaluation. The Osservatorio Epidemiologico sulla Sincope Lazio and Canadian Syncope Risk Score achieved the largest AUC (0.701, 95% confidence interval [CI] 0.63-0.77 and 0.694, 95% CI 0.62-0.77, respectively). Yet, all scores provided relatively high sensitivity with low specificity. Multivariate regression revealed age ≥75 (adjusted odds ratio 3.50, 95% CI 1.5-7.9) and abnormal cardiac auscultation (adjusted odds ratio 4.79, 95% CI 2.5-9.1) to be independent predictors. Incorporating these factors led to a significantly higher prediction ability of the Osservatorio Epidemiologico sulla Sincope Lazio (AUC of 0.787, P < .01) and Canadian Syncope Risk Score (AUC 0.778, P < .01) modified scores.
CONCLUSIONS: Current syncope risk scores provide limited prediction ability for the outcomes of inpatient cardiac syncope work-up. One should specifically consider age > 75 years and either cardiac murmur or irregular heart rate on examination very significant in implying a cardiac etiology for syncope. Although these factors may be obvious, current risk scores can be interpreted in such a fashion that ignores the importance of findings extracted from a good history and physical examination.